Table 1.
The patients characteristics
| Clinicl charachteristic | Total No=50 | PTCH1 mutation No (%) | PTCHI normal No (%) |
|---|---|---|---|
| CML chronic phase | 31 (62) | 12 (38.7) | 19 (61.3) |
| CML accelerated phase | 11 (22) | 7 (63.6) | 4 (36.4) |
| CML blastic phase | 8 (16) | 5 (62.5) | 3 (37.5) |
| Response at 3 months No (%) | |||
| <10% BCR-ABL | 21 (44.7) | 10 (47.6) | 11 (52.4) |
| >10% BCR-ABL | 26 (55.3) | 13 (50) | 13 (50) |
| Response at 1 year | |||
| CCyR | 22 (51.2) | 11 (50) | 11 (50) |
| No CCyR | 21 (48.8) | 8 (38.1) | 13 (61.9) |
| Patients on Imatinip at last follow up | 39 | 20 (51.3) | 19 (48.7) |
| Imatinip failure | 6 | 5 (83.3) | 1 (16.7) |
| No imatinip failure | 37 | 14 (37.8) | 23 (62.2) |
| Imatinip discontinuation due to side effect | 4 | 3 (75) | 1 (25) |
| Evolution of chronic phase to AP/BC | 11 | 6 (54.5) | 5 (45.5) |
| Evolution of accelerated phase to Blastic crises | 2 | 1 (50) | 1 (50) |
| Deaths related to CML | 4 | 3 (75) | 1 (25) |
| Allo bone marrow transplantation | 0 | 0 | 0 |
| Patients lost during follow up | 3 | 2 (66.7) | 1 (33.3) |
CCyR: Complete cytogenetic response. AP: Accelerated phase. BC: Blastic crisis.